Kristen R. Ibanez

Kristen R. Ibanez

Auto-generated profile, based on publicly available information

Kristen R. Ibanez

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
EGElena Giudice
Elena Giudice
Tzu-Ting HuangTzu-Ting Huang
Tzu-Ting Huang
JNJayakumar R. Nair
Jayakumar R. Nair
GZGrant Zurcher
Grant Zurcher
AMAnn McCoy
Ann McCoy
JLJung-Min Lee
Jung-Min Lee
The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable disease (cohort 6). The primary endpoint was objective response rate (ORR). Secondary outcomes were safety and progression-free survival (PFS). 49 heavily pretreated patients were enrolled (24 in cohort 5, 25 in cohort 6). Among the 39 RECISTv1.1-evaluable patients, ORR was 33.3% in cohort 5 and 28.6% in cohort 6. Primary endpoint was not evaluable due to early stop of the trial. The median PFS was 4 months in cohort 5 and 6 months in cohort 6. Toxicity was manageable. Translational research was an exploratory endpoint. Potential biomarkers were investigated using pre-treatment fresh biopsies and serial blood samples. Transcriptomic analysis revealed high levels of DNA replication-related genes (POLA1, POLE, GINS3) associated with lack of clinical benefit [defined post-hoc as PFS < 6 months]. Subsequent preclinical experiments demonstrated significant cytotoxicity of POLA1 silencing in combination with CHK1i in platinum-resistant HGSOC cell line models. Therefore, POLA1 expression may be predictive for CHK1i resistance, and the concurrent POLA1 inhibition may improve the efficacy of CHK1i monotherapy in this hard-to-treat population, deserving further investigation.

19 June 2024 in Cells
Verified
Journal Article
Open access
PDF file
KIKristen R. Ibanez
Kristen R. Ibanez
Tzu-Ting HuangTzu-Ting Huang
Tzu-Ting Huang
JLJung-Min Lee
Jung-Min Lee
The PI3K signaling pathway plays an essential role in cancer cell proliferation and survival. PI3K pathway inhibitors are now FDA-approved as a single agent treatment or in combination for solid tumors such as renal cell carcinoma or breast cancer. However, despite the high prevalence of PI3K pathway alterations in gynecological cancers and promising preclinical activity in endometrial and ovarian cancer models, PI3K pathway inhibitors showed limited clinical activity in gynecological cancers. In this review, we provide an overview on resistance mechanisms against PI3K pathway inhibitors that limit their use in gynecological malignancies, including genetic alterations that reactivate the PI3K pathway such as PIK3CA mutations and PTEN loss, compensatory signaling pathway activation, and feedback loops causing the reactivation of the PI3K signaling pathway. We also discuss the successes and limitations of recent clinical trials aiming to address such resistance mechanisms through combination therapies.

7 November 2024 in Cells
Verified
Journal Article
Open access
PDF file
CSChi-Ting Shih
Chi-Ting Shih
Tzu-Ting HuangTzu-Ting Huang
Tzu-Ting Huang
JNJayakumar Nair
Jayakumar Nair
KIKristen R. Ibanez
Kristen R. Ibanez
JLJung-Min Lee
Jung-Min Lee
Poly (ADP-ribose) polymerase inhibitors (PARPis) show cytotoxicity in homologous recombination deficiency (HRD) seen in BRCA-mutant ovarian cancer (OvCa). Despite initial responses, resistance often develops. The reintroduction of different PARPis, such as niraparib or rucaparib, has shown some clinical activity in BRCA mutation-associated OvCa patients with prior olaparib treatment, yet the underlying mechanisms remain unclear. To investigate the differential sensitivity to different PARPis, we established an olaparib-resistant BRCA1-mutant OvCa cell line (UWB-OlaJR) by exposing UWB1.289 cells to gradually increasing concentrations of olaparib. UWB-OlaJR exhibited restored HR capability without BRCA1 reversion mutation or increased drug efflux. We examined cell viability, DNA damage, and DNA replication fork dynamics in UWB-OlaJR treated with various PARPis. UWB-OlaJR exhibits varying sensitivity to PARPis, showing cross-resistance to veliparib and talazoparib, and sensitivity with increased cytotoxicity to niraparib and rucaparib. Indeed, DNA fiber assay reveals that niraparib and rucaparib cause higher replication stress than the others. Moreover, S1 nuclease fiber assay shows that niraparib and rucaparib induce greater DNA single-strand gaps than other PARPis, leading to increased DNA damage and cell death. Our study provides novel insights into differential PARPi sensitivity in olaparib-resistant BRCA-mutant OvCa, which requires further investigation of inter-agent differences in large prospective studies.

22 September 2023 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
DGDavid G. Gelikman
David G. Gelikman
KIKristen R. Ibanez
Kristen R. Ibanez
YGYasmine S. Ghattas
Yasmine S. Ghattas
ECEmily Craver
Emily Craver
ACAdela T. Casas-Melley
Adela T. Casas-Melley
ASAbhishek Seth
Abhishek Seth

1 May 2025 in JCO Global Oncology
Verified
Journal Article
Open access
MKMaheen H. Khan
Maheen H. Khan
KIKristen R. Ibanez
Kristen R. Ibanez
CBCourtney Bowen
Courtney Bowen
DDDuncan Donohue
Duncan Donohue
AOAnn Oluloro
Ann Oluloro
JLJung-Min Lee
Jung-Min Lee
PURPOSE: To evaluate the impact of international enrollment in landmark gynecologic cancer (Gyn-Ca) trials that supported the US Food and Drug Administration (FDA) drug approvals. METHODS: We examined the FDA drug approval database for approved Gyn-Ca agents between January 2014 and June 2024. We then extracted clinical trial identifiers supporting these approvals using FDA safety labels. Expected enrollment was calculated using gynecologic disease site incidence data from the US Cancer Statistics Program and compared with actual trial enrollment reported on ClinicalTrials.gov. RESULTS: From 2014 to 2024, 30 Gyn-Ca trials supporting 28 FDA approvals were conducted in US/international (86.7%), international-only (10%), and US-only sites (3.3%) and enrolled 15,294 patients, with 14,053 remaining (74.0% White, 4.1% Black, 12.7% Asian, 8.7% other) after screening for trials not reporting race. Black (–11.0%; P < .0001), Hispanic/Latino (–3.5%; P < .0001), and elderly (–12.6%; P < .0001) participants were under-represented, whereas Asians (+6.8%; P < .0001) were over-represented. Asian (18.3% v 3.5% in trials with or without East Asian sites; odds ratio [OR], 6.19 [95% CI, 5.29 to 7.25]; P < .0001) and Hispanic/Latino (18.6% v 4.6% in trials with or without South American sites; OR, 4.75 [95% CI, 4.00 to 5.63]; P < .0001) enrollment was higher in trials that included East Asian and South American sites, respectively. Black enrollment did not improve despite trials including recruitment in Africa (3.2% v 4.1% Black enrollment in trials with or without African sites; OR, 0.83 [95% CI, 0.38 to 1.83]; P = .53). CONCLUSION: Black, Hispanic/Latino, and elderly patients were under-represented in pivotal Gyn-Ca trials, whereas Asian patients were over-represented, compared with expected enrollment proportions. Postmarketing studies on under-represented groups should be considered to assess drug efficacy and safety in these populations.

1 January 2024 in Journal of Endourology
Verified
Journal Article
Closed access
DGDavid G. Gelikman
David G. Gelikman
KIKristen R. Ibanez
Kristen R. Ibanez
ARAmy M. Reed
Amy M. Reed
RHRyan S. Hsi
Ryan S. Hsi
NNNaren Nimmagadda
Naren Nimmagadda
NMNicole L. Miller
Nicole L. Miller
Introduction: Holmium laser lithotripsy is a standard energy source used for treatment of kidney stones during flexible ureteroscopy. Efficiency of laser surgery may be affected by patient and operator characteristics or perioperative management. Here, we sought to examine intraoperative data from patients undergoing high frequency dusting with high-powered holmium laser lithotripsy to evaluate surgical and demographic factors associated with lasing efficiency. Methods: A total of 82 intraoperative reports were analyzed from an ongoing laser lithotripsy clinical trial evaluating the Lumenis Pulse™ 120H holmium laser with renal stones up to 20mm in diameter with and without Moses 2.0 technology. For each case, the total pause time between lasing activations was corrected to remove lengthy pauses and divided by the total lasing time to calculate an efficiency percentage. This was then compared with patient demographics, anesthesia administration, stone burden, postoperative complications, and stone-free rates using both univariate and multivariate analyses. Results: Of the 82 included patients, 36 received endotracheal intubation (ETT) and 46 had a laryngeal mask airway (LMA). Patients with ETT had significantly higher lasing efficiency (78.7%) compared to those with an LMA (73.3%) in our univariate analysis (p < .01) as well as in the multivariate model that adjusted for maximum stone size, number of stones, stone density, and patient BMI (p < .05). There was also significantly higher mean lasing efficiency in patients with no postoperative complications (76.3%) compared to those with any grade (I-V) Clavien-Dindo complication within 30 days after surgery (70.0%) (p < .05). Conclusions: Flexible ureteroscopy and laser lithotripsy (fURSL) cases with higher lasing efficiency are associated with lower rates of postoperative complications. The data also supports the use of ETT over LMA to improve overall lasing efficiency, however, this remains one consideration among many for choosing anesthesia administration.